Ledipasvir/sofosbuvir fixed‐dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus
Wan‐Long Chuang(Kaohsiung Medical University), Jia‐Horng Kao(National Taiwan University Hospital), Kimberly L. Garrison(Gilead Sciences (United States)), Phillip S. Pang(Gilead Sciences (United States)), Jyh‐Jou Chen(Tainan University of Technology), Steven Knox(Gilead Sciences (United States)), Rong‐Nan Chien(Chang Gung Memorial Hospital), Tsung‐Hui Hu(National Sun Yat-sen University), Bing Gao(Sun Yat-sen University), Cheng‐Yuan Peng(China Medical University), Horng‐Yuan Wang(Mackay Memorial Hospital), Jenny C. Yang(Gilead Sciences (United States)), Yu‐Chun Hsu(The University of Texas Health Science Center at Houston), Chi‐Jen Chu(Taipei Veterans General Hospital), Ting‐Tsung Chang(National Cheng Kung University Hospital), Hongmei Mo(Gilead Sciences (United States)), I‐Shyan Sheen(Chang Gung University), Gin‐Ho Lo(E-Da Hospital)
Cited by 27
Related Papers
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
|Gastroenterology|2006|882